Table 2. Univariate analysis of NSCLC patient prognosis (n=54).
| Variable | Survival rate (%) | mOS (months) | P-value | ||
|---|---|---|---|---|---|
| 3 years | 5 years | 8 years | |||
| Gender | 0.179 | ||||
| Female | 70.0 | 70.0 | 50.0 | 84.0 | |
| Male | 63.6 | 47.7 | 27.3 | 58.0 | |
| Age at diagnosis (years) | 0.165 | ||||
| ≤60 | 74.1 | 55.6 | 40.7 | 70.0 | |
| >60 | 55.6 | 48.1 | 40.7 | 58.0 | |
| AJCC stage | 0.015 | ||||
| I/II | 71.8 | 61.5 | 38.5 | 82.0 | |
| III/IV | 46.7 | 26.7 | 13.3 | 24.0 | |
| T stage | 0.238 | ||||
| T1/2 | 68.2 | 54.5 | 34.1 | 67.0 | |
| T3/4 | 50.0 | 40.0 | 20.0 | 24.0 | |
| Lymphatic metastasis | 0.003 | ||||
| No | 77.8 | 70.4 | 48.1 | 90.0 | |
| Yes | 51.9 | 33.3 | 14.8 | 36.0 | |
| Tumor type | 0.151 | ||||
| SC | 62.5 | 56.3 | 28.1 | 62.0 | |
| AC | 71.4 | 47.6 | 38.1 | 58.0 | |
| ASC | 0 | 0 | 0 | 8.0 | |
| MTA1 expression | 0.048 | ||||
| Negative | 84.6 | 76.9 | 53.8 | Not reach | |
| Positive | 58.5 | 43.9 | 24.4 | 42.0 | |
AJCC: American Joint Committee on Cancer.
SC: squamous carcinoma; AC adenocarcinoma; ASC: adeno-squamous carcinoma.
mOS, median overall survival time.
Significant P-values are bolded (P<0.05).